Comparative Pharmacology
Head-to-head clinical analysis: OMONTYS versus RETACRIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMONTYS versus RETACRIT.
OMONTYS vs RETACRIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythropoiesis-stimulating agent; synthetic peptide agonist of the erythropoietin receptor (EPOR) that stimulates erythropoiesis in red blood cell precursors.
RETACRIT (epoetin alfa-epbx) is a recombinant human erythropoietin that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation into mature red blood cells.
45 mg subcutaneously once every 4 weeks (monthly) in adults.
50-100 IU/kg intravenously or subcutaneously three times weekly; initial dose 50 IU/kg three times weekly, titrated to target hemoglobin 10-12 g/dL.
None Documented
None Documented
Terminal elimination half-life is approximately 14.5 hours in healthy adults; in hemodialysis patients, half-life is extended to 26.4–29.9 hours, supporting weekly dosing.
Terminal elimination half-life is ~2.5-4.5 hours following intravenous administration; shorter in children; prolonged in hepatic impairment.
Primarily eliminated via the reticuloendothelial system; no significant renal or biliary excretion. The iron component is incorporated into hemoglobin or stored as ferritin/hemosiderin.
Primarily hepatic metabolism; ~10% excreted unchanged in urine, remainder via feces as metabolites.
Category C
Category C
Erythropoiesis-Stimulating Agent
Erythropoiesis-Stimulating Agent